Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, TEXAS, November 1, 2024 – Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Nexalin Technology’s 8K filing here.

Nexalin Technology Company Profile

(Get Free Report)

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.

Featured Stories